83 related articles for article (PubMed ID: 12828471)
61. 19-epi-okadaic acid, a novel protein phosphatase inhibitor with enhanced selectivity.
Cruz PG; Daranas AH; Fernández JJ; Norte M
Org Lett; 2007 Aug; 9(16):3045-8. PubMed ID: 17630753
[TBL] [Abstract][Full Text] [Related]
62. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A.
Roberge M; Tudan C; Hung SM; Harder KW; Jirik FR; Anderson H
Cancer Res; 1994 Dec; 54(23):6115-21. PubMed ID: 7954457
[TBL] [Abstract][Full Text] [Related]
63. Inhibition of PP2A, but not PP5, mediates p53 activation by low levels of okadaic acid in rat liver epithelial cells.
Messner DJ; Romeo C; Boynton A; Rossie S
J Cell Biochem; 2006 Sep; 99(1):241-55. PubMed ID: 16598789
[TBL] [Abstract][Full Text] [Related]
64. Inhibition of the G2 DNA damage checkpoint by oliveroline isolated from Duguetia odorata.
Brastianos HC; Sturgeon CM; Roberge M; Andersen RJ
J Nat Prod; 2007 Feb; 70(2):287-8. PubMed ID: 17315964
[TBL] [Abstract][Full Text] [Related]
65. Cell cycle checkpoints and their impact on anticancer therapeutic strategies.
Eastman A
J Cell Biochem; 2004 Feb; 91(2):223-31. PubMed ID: 14743382
[TBL] [Abstract][Full Text] [Related]
66. Analyzing the G2/M checkpoint.
Stark GR; Taylor WR
Methods Mol Biol; 2004; 280():51-82. PubMed ID: 15187249
[TBL] [Abstract][Full Text] [Related]
67. From DNA damage to G2 arrest: the many roles of topoisomerase II.
Larsen AK; Escargueil AE; Skladanowski A
Prog Cell Cycle Res; 2003; 5():295-300. PubMed ID: 14593724
[TBL] [Abstract][Full Text] [Related]
68. Effect of okadaic acid on glucose regulation.
Louzao MC; Vieytes MR; Botana LM
Mini Rev Med Chem; 2005 Feb; 5(2):207-15. PubMed ID: 15720290
[TBL] [Abstract][Full Text] [Related]
69. [Total synthesis and conformational analysis of inhibitors].
Tsuboi K; Isobe M
Tanpakushitsu Kakusan Koso; 1998 Jun; 43(8 Suppl):1083-90. PubMed ID: 9655966
[No Abstract] [Full Text] [Related]
70. A pharmacophore model of tautomycin, an inhibitor of protein phosphatases 1 and 2A.
Ubukata M; Koshino H; Yamasaki C; Fujita K; Isono K
J Antibiot (Tokyo); 1997 Oct; 50(10):801-7. PubMed ID: 9402983
[No Abstract] [Full Text] [Related]
71. Biotherapeutic potential and synthesis of okadaic acid.
Forsyth CJ; Dounay AB; Sabes SF; Urbanek RA
Ernst Schering Res Found Workshop; 2000; (32):57-102. PubMed ID: 11077606
[No Abstract] [Full Text] [Related]
72. New okadaic acid analogues from the marine sponge Merriamum oxeato and their effect on mitosis.
Britton R; Roberge M; Brown C; van Soest R; Andersen RJ
J Nat Prod; 2003 Jun; 66(6):838-43. PubMed ID: 12828471
[TBL] [Abstract][Full Text] [Related]
73. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy.
Anderson HJ; Andersen RJ; Roberge M
Prog Cell Cycle Res; 2003; 5():423-30. PubMed ID: 14593736
[TBL] [Abstract][Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
